IPAMORELIN (10mg)

Ipamorelin 10mg, a selective growth hormone secretagogue for GH research. (99%) Purity verified here on Australian soil at The University of Melbourne.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue originally developed by Novo Nordisk (research code NNC 26-0161). It acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), which is the same receptor targeted by ghrelin, the endogenous hunger hormone.

The peptide sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) includes several modified amino acids that contribute to its selectivity and stability. Research has characterised Ipamorelin as one of the most selective GHS-R1a agonists available, with minimal effects on cortisol, prolactin, and other hormones in preclinical studies.

Studies have compared Ipamorelin’s pharmacology with other growth hormone secretagogues including GHRP-6, GHRP-2, and hexarelin. Research indicates that Ipamorelin demonstrates dose-dependent GH release with a more favourable selectivity profile than earlier generation secretagogues.

The peptide has been studied in various research contexts examining the GH/IGF-1 axis, including investigations into pulsatile versus continuous GH release patterns. Research has also explored its potential interactions with GHRH analogues in combined administration protocols.

Gen Ex Peptides supplies Ipamorelin tested at an Australian university laboratory not generic overseas certificates. Each batch is verified for purity (99%) using HPLC and mass spectrometry.